- Home
- REAL vs EDIT Comparison
REAL vs EDIT Comparison
Compare REAL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- EDIT
- Stock Information
- Founded
- REAL 2011
- EDIT 2013
- Country
- REAL United States
- EDIT United States
- Employees
- REAL N/A
- EDIT N/A
- Industry
- REAL Other Specialty Stores
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REAL Consumer Discretionary
- EDIT Health Care
- Exchange
- REAL Nasdaq
- EDIT Nasdaq
- Market Cap
- REAL 295.1M
- EDIT 327.0M
- IPO Year
- REAL 2019
- EDIT 2016
- Fundamental
- Price
- REAL $3.01
- EDIT $3.29
- Analyst Decision
- REAL Buy
- EDIT Buy
- Analyst Count
- REAL 7
- EDIT 10
- Target Price
- REAL $3.96
- EDIT $10.50
- AVG Volume (30 Days)
- REAL 1.4M
- EDIT 2.0M
- Earning Date
- REAL 11-04-2024
- EDIT 11-01-2024
- Dividend Yield
- REAL N/A
- EDIT N/A
- EPS Growth
- REAL N/A
- EDIT N/A
- EPS
- REAL N/A
- EDIT N/A
- Revenue
- REAL $565,279,000.00
- EDIT $67,034,000.00
- Revenue This Year
- REAL $8.79
- EDIT N/A
- Revenue Next Year
- REAL $8.29
- EDIT N/A
- P/E Ratio
- REAL N/A
- EDIT N/A
- Revenue Growth
- REAL N/A
- EDIT 247.04
- 52 Week Low
- REAL $1.26
- EDIT $2.91
- 52 Week High
- REAL $4.64
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- REAL 45.80
- EDIT 45.89
- Support Level
- REAL $3.06
- EDIT $3.25
- Resistance Level
- REAL $3.38
- EDIT $3.80
- Average True Range (ATR)
- REAL 0.16
- EDIT 0.23
- MACD
- REAL -0.04
- EDIT 0.05
- Stochastic Oscillator
- REAL 20.35
- EDIT 42.70
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.